drugset / Trial / NCT03840902
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Phase 2
Terminated
153 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Timeline
- Start
- 2019-04-16
- Primary completion
- 2023-02-17
- Completion
- 2023-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bintrafusp alfa | Protein / enzyme biologic | 1200 mg | Intravenous |
| Comparator | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 50 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 45 mg/m2 | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |